Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease
Authors
Keywords
-
Journal
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 39, Issue 12, Pages 1349-1362
Publisher
Wiley
Online
2014-04-21
DOI
10.1111/apt.12749
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treat to Target: A Proposed New Paradigm for the Management of Crohn's Disease
- (2015) Guillaume Bouguen et al. Clinical Gastroenterology and Hepatology
- Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis
- (2014) R. W. Stidham et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: An indirect treatment comparison meta-analysis
- (2014) Kristian Thorlund et al. Journal of Crohns & Colitis
- A UK retrospective observational study of clinical outcomes and healthcare resource utilisation of infliximab treatment in Crohn's disease
- (2013) J. O. Lindsay et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Infectious and Malignant Complications of TNF Inhibitor Therapy in IBD
- (2013) Laura E Targownik et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Adalimumab and Infliximab Are Equally Effective for Crohn's Disease in Patients Not Previously Treated With Anti–Tumor Necrosis Factor-α Agents
- (2013) Christine Kestens et al. Clinical Gastroenterology and Hepatology
- Comparative Effectiveness of Infliximab and Adalimumab for Crohn's Disease
- (2013) Mark T. Osterman et al. Clinical Gastroenterology and Hepatology
- Inflammatory Bowel Disease Is Associated With an Increased Risk of Melanoma: A Systematic Review and Meta-analysis
- (2013) Siddharth Singh et al. Clinical Gastroenterology and Hepatology
- Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease
- (2013) Grace K.H. Choi et al. Journal of Crohns & Colitis
- Comparative Effectiveness of Anti-Tumor Necrosis Factor Drugs on Health-Related Quality of Life Among Patients With Inflammatory Arthritis
- (2013) Jian Sheng Chen et al. ARTHRITIS CARE & RESEARCH
- Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study
- (2012) F. Zorzi et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Why the findings of published multiple treatment comparison meta-analyses of biologic treatments for rheumatoid arthritis are different: an overview of recurrent methodological shortcomings
- (2012) Kristian Thorlund et al. ANNALS OF THE RHEUMATIC DISEASES
- Placental Transfer of Anti–Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel Disease
- (2012) Uma Mahadevan et al. Clinical Gastroenterology and Hepatology
- Comparative Effectiveness of Anti-TNF Agents for Crohn’s Disease in a Tertiary Referral IBD Practice
- (2012) Seema A. Patil et al. DIGESTIVE DISEASES AND SCIENCES
- Comparison of medical costs among patients using adalimumab and infliximab: A retrospective study (COMPAIRS)
- (2012) Daniel A. Sussman et al. INFLAMMATORY BOWEL DISEASES
- Automating network meta-analysis
- (2012) Gert van Valkenhoef et al. Research Synthesis Methods
- Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
- (2011) Alexander C Ford et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial
- (2011) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- The Utility of Biomarkers in the Diagnosis and Therapy of Inflammatory Bowel Disease
- (2011) James D. Lewis GASTROENTEROLOGY
- Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial
- (2011) Gert Van Assche et al. GUT
- Development of the Crohnʼs disease digestive damage score, the Lémann score
- (2010) Benjamin Pariente et al. INFLAMMATORY BOWEL DISEASES
- Fecal Calprotectin Correlates More Closely With the Simple Endoscopic Score for Crohn's Disease (SES-CD) than CRP, Blood Leukocytes and the CDAI
- (2009) Alain M Schoepfer et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis
- (2009) Sophie Martin Du Pan et al. ARTHRITIS AND RHEUMATISM
- Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis
- (2009) Corey A. Siegel et al. Clinical Gastroenterology and Hepatology
- Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor
- (2009) Zehra Kaymakcalan et al. CLINICAL IMMUNOLOGY
- Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohnʼs disease
- (2009) Edward V. Loftus et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease
- (2009) J. Rimola et al. GUT
- Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study)
- (2009) S. Scarpato et al. RHEUMATOLOGY
- Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials
- (2008) Laurent Peyrin–Biroulet et al. Clinical Gastroenterology and Hepatology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More